Published in BMC Cancer on November 30, 2011
The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal (2014) 2.26
The rationale for targeting the LOX family in cancer. Nat Rev Cancer (2012) 2.02
Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem (2013) 1.40
Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol (2014) 1.17
Photodynamic nanomedicine in the treatment of solid tumors: perspectives and challenges. J Control Release (2013) 1.05
Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol (2014) 0.99
Brachytherapy application with in situ dose painting administered by gold nanoparticle eluters. Int J Radiat Oncol Biol Phys (2014) 0.99
Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. Proc Natl Acad Sci U S A (2014) 0.98
Hypoxia-inducible factor 1α (HIF-1α) and reactive oxygen species (ROS) mediates radiation-induced invasiveness through the SDF-1α/CXCR4 pathway in non-small cell lung carcinoma cells. Oncotarget (2015) 0.97
Non-Toxic Metabolic Management of Metastatic Cancer in VM Mice: Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy. PLoS One (2015) 0.95
Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Dis Model Mech (2012) 0.90
Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89
Sickle erythrocytes target cytotoxics to hypoxic tumor microvessels and potentiate a tumoricidal response. PLoS One (2013) 0.89
Prodrug applications for targeted cancer therapy. AAPS J (2014) 0.87
Mechanistic insights into self-reinforcing processes driving abnormal histogenesis during the development of pancreatic cancer. Am J Pathol (2013) 0.86
HDAC6 deacetylase activity is required for hypoxia-induced invadopodia formation and cell invasion. PLoS One (2013) 0.84
NEU3 sialidase is activated under hypoxia and protects skeletal muscle cells from apoptosis through the activation of the epidermal growth factor receptor signaling pathway and the hypoxia-inducible factor (HIF)-1α. J Biol Chem (2012) 0.82
A decade of progress in cancer research. BMC Cancer (2011) 0.79
A platelet-mimetic paradigm for metastasis-targeted nanomedicine platforms. Biomacromolecules (2013) 0.79
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. BMC Cancer (2016) 0.78
Tg737 signaling is required for hypoxia-enhanced invasion and migration of hepatoma cells. J Exp Clin Cancer Res (2012) 0.78
Carving out its niche: A role for carbonic anhydrase IX in pre-metastatic niche development. Oncoimmunology (2015) 0.77
15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1α expression in human colon cancer cells. Cancer Med (2014) 0.77
Can we negotiate with a tumor? PLoS One (2014) 0.76
Spatio-Temporal Dynamics of Hypoxia during Radiotherapy. PLoS One (2015) 0.76
Oxygen Sensing with Perfluorocarbon-Loaded Ultraporous Mesostructured Silica Nanoparticles. ACS Nano (2017) 0.75
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
Cancer metastasis: building a framework. Cell (2006) 19.67
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Tumor metastasis: mechanistic insights and clinical challenges. Nat Med (2006) 11.06
A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol (1992) 11.03
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer (2004) 7.91
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res (1996) 6.62
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res (1998) 5.86
Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature (2003) 5.57
Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res (1996) 4.98
Integration of oxygen signaling at the consensus HRE. Sci STKE (2005) 4.95
Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem (2003) 4.58
Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer (2008) 4.43
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol (2010) 4.34
The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ (2008) 4.31
HIF-1 as a target for drug development. Nat Rev Drug Discov (2003) 3.07
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst (2003) 2.91
Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol (2002) 2.82
Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid Res Mol Biol (2001) 2.69
A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res (2002) 2.65
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol (2008) 2.56
Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev (2007) 2.52
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem (2008) 2.35
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther (2004) 2.32
CXCR4: chemokine receptor extraordinaire. Immunol Rev (2000) 2.16
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010) 2.12
Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med (2009) 2.09
Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res (1993) 1.97
Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer (1995) 1.96
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res (2005) 1.95
SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys (1986) 1.87
18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med (2008) 1.77
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res (2011) 1.76
Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res (2007) 1.60
Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med (2003) 1.54
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res (2011) 1.49
Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res (2007) 1.45
CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des (2010) 1.33
Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. Int J Cancer (2010) 1.30
Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol) (2007) 1.28
Influence of tumour size on hypoxic fraction and therapeutic sensitivity of Lewis lung tumour. Br J Cancer (1977) 1.24
Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev (1993) 1.24
Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res (2008) 1.20
AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer (1995) 1.18
Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem (2011) 1.13
Hypoxia in microscopic tumors. Cancer Lett (2008) 1.04
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol (2009) 1.03
DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. Cancer Res (2009) 0.99
Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs (2009) 0.96
Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer. Int J Radiat Oncol Biol Phys (2001) 0.95
Increased expression of metastasis-related genes in hypoxic cells sorted from cervical and lymph nodal xenograft tumors. Lab Invest (2009) 0.95
High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia. J Nucl Med (2010) 0.93
Design, synthesis, and biological evaluation of novel carbohydrate-based sulfamates as carbonic anhydrase inhibitors. J Med Chem (2011) 0.92
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clin Cancer Res (2008) 0.89
Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography. Eur J Nucl Med Mol Imaging (2009) 0.89
Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer. Clin Cancer Res (2007) 0.89
The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection. Curr Med Chem (2011) 0.89
Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. Clin Cancer Res (2005) 0.83
Development of hypoxia in a preclinical model of tumor micrometastases. Int J Radiat Oncol Biol Phys (2010) 0.83
The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy. Br J Cancer (2010) 0.82
More lessons learned from the suffocation of hypoxia. J Clin Oncol (2010) 0.78
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study. Ann Oncol (2007) 0.78
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer (2005) 3.83
NGF-induced axon growth is mediated by localized inactivation of GSK-3beta and functions of the microtubule plus end binding protein APC. Neuron (2004) 3.72
Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem (2002) 3.18
Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev (2005) 2.87
Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene (2004) 2.44
Integrin-linked kinase--essential roles in physiology and cancer biology. J Cell Sci (2008) 2.43
Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res (2008) 2.20
Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons. Proc Natl Acad Sci U S A (2008) 2.06
Reduced chondrocyte proliferation and chondrodysplasia in mice lacking the integrin-linked kinase in chondrocytes. J Cell Biol (2003) 1.99
Essential role of integrin-linked kinase in podocyte biology: Bridging the integrin and slit diaphragm signaling. J Am Soc Nephrol (2006) 1.90
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene (2005) 1.89
Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell (2004) 1.82
Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. Genes Dev (2006) 1.80
Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem (2003) 1.77
Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget (2012) 1.77
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res (2011) 1.76
Podocyte-specific deletion of integrin-linked kinase results in severe glomerular basement membrane alterations and progressive glomerulosclerosis. J Am Soc Nephrol (2006) 1.70
SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem (2005) 1.70
Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res (2005) 1.69
Novel role for integrin-linked kinase in modulation of coxsackievirus B3 replication and virus-induced cardiomyocyte injury. Circ Res (2006) 1.60
Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol (2006) 1.59
The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Rev (2003) 1.59
Tubular epithelial cell dedifferentiation is driven by the helix-loop-helix transcriptional inhibitor Id1. J Am Soc Nephrol (2007) 1.56
Integrin-linked kinase localizes to the centrosome and regulates mitotic spindle organization. J Cell Biol (2008) 1.53
ILK mediates actin filament rearrangements and cell migration and invasion through PI3K/Akt/Rac1 signaling. Oncogene (2005) 1.46
Integrin-linked kinase regulates endothelial cell survival and vascular development. Mol Cell Biol (2004) 1.46
Integrin-linked kinase at the heart of cardiac contractility, repair, and disease. Circ Res (2007) 1.44
Integration of cell attachment, cytoskeletal localization, and signaling by integrin-linked kinase (ILK), CH-ILKBP, and the tumor suppressor PTEN. Mol Biol Cell (2003) 1.38
alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene (2003) 1.36
Neurotrophins support regenerative axon assembly over CSPGs by an ECM-integrin-independent mechanism. J Cell Sci (2006) 1.35
Integrin-linked kinase deletion from mouse cortex results in cortical lamination defects resembling cobblestone lissencephaly. J Neurosci (2005) 1.35
Integrin-linked kinase activity regulates Rac- and Cdc42-mediated actin cytoskeleton reorganization via alpha-PIX. Oncogene (2005) 1.34
Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochim Biophys Acta (2004) 1.32
Liver-specific ablation of integrin-linked kinase in mice results in abnormal histology, enhanced cell proliferation, and hepatomegaly. Hepatology (2008) 1.31
Integrin-linked kinase is a functional Mn2+-dependent protein kinase that regulates glycogen synthase kinase-3β (GSK-3beta) phosphorylation. PLoS One (2010) 1.31
Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res (2006) 1.31
Epithelial-mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis. Dev Dyn (2008) 1.29
Mapping the integrin-linked kinase interactome using SILAC. J Proteome Res (2008) 1.25
Role of the integrin-linked kinase/PINCH1/alpha-parvin complex in cardiac myocyte hypertrophy. Lab Invest (2005) 1.18
BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways. J Cell Biol (2011) 1.16
Role of integrin-linked kinase in nerve growth factor-stimulated neurite outgrowth. J Neurosci (2003) 1.15
Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene (2005) 1.14
Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem (2011) 1.13
Critical role of integrin-linked kinase in granule cell precursor proliferation and cerebellar development. J Neurosci (2006) 1.11
Molecular dissection of integrin signalling proteins in the control of mammary epithelial development and differentiation. Development (2009) 1.11
Impaired hair follicle morphogenesis and polarized keratinocyte movement upon conditional inactivation of integrin-linked kinase in the epidermis. Mol Biol Cell (2008) 1.11
Loss of integrin linked kinase from mouse hepatocytes in vitro and in vivo results in apoptosis and hepatitis. Hepatology (2007) 1.10
Integrin-linked kinase is an essential link between integrins and uptake of bacterial pathogens by epithelial cells. Cell Microbiol (2006) 1.09
A dual role for integrin-linked kinase in platelets: regulating integrin function and alpha-granule secretion. Blood (2008) 1.09
Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol Cancer Ther (2006) 1.08
The importance of integrin-linked kinase in the regulation of bladder cancer invasion. Int J Cancer (2011) 1.02
Targeted deletion of integrin-linked kinase reveals a role in T-cell chemotaxis and survival. Mol Cell Biol (2005) 1.01
Integrin-linked kinase regulates inducible nitric oxide synthase and cyclooxygenase-2 expression in an NF-kappa B-dependent manner. J Biol Chem (2001) 0.99
Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther (2006) 0.99
Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. Carcinogenesis (2012) 0.98
Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol Cancer Ther (2008) 0.98
The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth. Mol Cancer Ther (2007) 0.95
Role of the integrin-linked kinase (ILK) in determining neuronal polarity. Dev Biol (2007) 0.95
Deletion of integrin-linked kinase from skeletal muscles of mice resembles muscular dystrophy due to alpha 7 beta 1-integrin deficiency. Am J Pathol (2007) 0.95
An essential role for the integrin-linked kinase-glycogen synthase kinase-3 beta pathway during dendrite initiation and growth. J Neurosci (2006) 0.94
Integrin-linked kinase regulates the nuclear entry of the c-Jun coactivator alpha-NAC and its coactivation potency. J Biol Chem (2004) 0.94
Novel matrix metalloproteinase inhibitor [18F]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer. Cancer Res (2010) 0.93
Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells. Cancer Res (2006) 0.92
Integrin-linked kinase regulates E-cadherin expression through PARP-1. Dev Dyn (2008) 0.91
Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells. Exp Hematol (2009) 0.91
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem (2011) 0.91
Beyond focal adhesions: integrin-linked kinase associates with tubulin and regulates mitotic spindle organization. Cell Cycle (2008) 0.89
Interaction of smoothened with integrin-linked kinase in primary cilia mediates Hedgehog signalling. EMBO Rep (2013) 0.89
The tumor invasion inhibitor dihydromotuporamine C activates RHO, remodels stress fibers and focal adhesions, and stimulates sodium-proton exchange. Cancer Res (2004) 0.88
The mitotic functions of integrin-linked kinase. Cancer Metastasis Rev (2009) 0.87
Role of integrin-linked kinase in leukocyte recruitment. J Biol Chem (2002) 0.87
Integrin-linked kinase (ILK) modulates wound healing through regulation of hepatocyte growth factor (HGF). Exp Cell Res (2012) 0.85
Aortic aneurysm generation in mice with targeted deletion of integrin-linked kinase in vascular smooth muscle cells. Circ Res (2011) 0.85
Carbonic anhydrase IX (CAIX) as a mediator of hypoxia-induced stress response in cancer cells. Subcell Biochem (2014) 0.84
Cooperative signaling between Wnt1 and integrin-linked kinase induces accelerated breast tumor development. Breast Cancer Res (2010) 0.84
Integrin-linked kinase regulates interphase and mitotic microtubule dynamics. PLoS One (2013) 0.83
Integrin-linked kinase regulates integrin signaling in human trabecular meshwork cells. Invest Ophthalmol Vis Sci (2011) 0.83
Integrin-linked kinase (ILK) in combination molecular targeting. Cancer Treat Res (2004) 0.83
Integrin-linked kinase functions as a downstream signal of platelet-derived growth factor to regulate actin polymerization and vascular smooth muscle cell migration. BMC Cell Biol (2010) 0.83
Role of epithelial integrin-linked kinase in promoting intestinal inflammation: effects on CCL2, fibronectin and the T cell repertoire. BMC Immunol (2011) 0.83
Identification of novel small molecule inhibitors of centrosome clustering in cancer cells. Oncotarget (2013) 0.83
Paxillin phosphorylation: bifurcation point downstream of integrin-linked kinase (ILK) in streptococcal invasion. Cell Microbiol (2007) 0.83
Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leuk Res (2010) 0.82
Osteoclast-specific inactivation of the integrin-linked kinase (ILK) inhibits bone resorption. J Cell Biochem (2010) 0.81
Integrin-linked kinase deletion in the developing lens leads to capsule rupture, impaired fiber migration and non-apoptotic epithelial cell death. Invest Ophthalmol Vis Sci (2012) 0.81
Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK). Transl Oncogenomics (2007) 0.79
Synthesis and evaluation of 18F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography. J Enzyme Inhib Med Chem (2013) 0.79
Deep sequence analysis of gene expression identifies osteopontin as a downstream effector of integrin-linked kinase (ILK) in cardiac-specific ILK knockout mice. Circ Heart Fail (2013) 0.78
Inactivation of the integrin-linked kinase (ILK) in osteoblasts increases mineralization. Gene (2013) 0.77
f-[18F]fluoroethanol and 3-[18F]fluoropropanol: facile preparation, biodistribution in mice, and their application as nucleophiles in the synthesis of [18F]fluoroalkyl aryl ester and ether PET tracers. Nucl Med Biol (2013) 0.76
Ilk conditional deletion in adult animals increases cyclic GMP-dependent vasorelaxation. Cardiovasc Res (2013) 0.76
Integrin-linked kinase: both Jekyll and Hyde in rhabdomyosarcoma. J Clin Invest (2009) 0.75